Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
作者信息
Vasey P A, Kaye S B
出版信息
Br J Cancer. 1997;76(11):1395-7. doi: 10.1038/bjc.1997.568.
Abstract
摘要
相似文献
1
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?拓扑异构酶I和II的联合抑制——这是一个值得/可行的策略吗？
Br J Cancer. 1997;76(11):1395-7. doi: 10.1038/bjc.1997.568.
2
Clinical use of topoisomerase I inhibitors in anticancer treatment.拓扑异构酶I抑制剂在抗癌治疗中的临床应用。
Med Pediatr Oncol. 2000 Oct;35(4):385-402. doi: 10.1002/1096-911x(20001001)35:4<385::aid-mpo1>3.0.co;2-e.
3
Phase I clinical trial of weekly combined topotecan and irinotecan.拓扑替康与伊立替康每周联合用药的I期临床试验。
Am J Clin Oncol. 2001 Aug;24(4):336-40. doi: 10.1097/00000421-200108000-00003.
4
The development of camptothecin analogs in childhood cancers.喜树碱类似物在儿童癌症中的发展。
Oncologist. 2001;6(6):506-16. doi: 10.1634/theoncologist.6-6-506.
5
Clinical development of topoisomerase-interactive drugs.拓扑异构酶相互作用药物的临床开发。
Adv Pharmacol. 1994;29B:1-31. doi: 10.1016/s1054-3589(08)61129-1.
6
Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?评论：拓扑异构酶作为急性白血病的治疗靶点：仅针对I型、II型、I型加II型还是都不针对？
Leuk Res. 2003 Jan;27(1):1-3. doi: 10.1016/s0145-2126(02)00219-9.
7
An overview of topoisomerase I-targeting agents.靶向拓扑异构酶I药物概述。
Semin Hematol. 1998 Jul;35(3 Suppl 4):3-12.
8
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.
Cancer Treat Rev. 1998 Jun;24(3):205-20. doi: 10.1016/s0305-7372(98)90050-0.
9
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.拓扑异构酶 1 抑制在转移性乳腺癌治疗中的系统评价。
Breast Cancer Res Treat. 2013 Apr;138(2):347-58. doi: 10.1007/s10549-013-2476-3. Epub 2013 Mar 20.
10
Colorectal cancer chemotherapy: irinotecan.
Semin Oncol. 2000 Oct;27(5 Suppl 10):138-43.
引用本文的文献
1
Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis.伊立替康所致腹泻的防护干预措施的效果：系统评价和荟萃分析。
Integr Cancer Ther. 2024 Jan-Dec;23:15347354241242110. doi: 10.1177/15347354241242110.
2
Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.伊立替康——癌症化疗中的重要角色：全面概述。
Int J Mol Sci. 2020 Jul 12;21(14):4919. doi: 10.3390/ijms21144919.
3
Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan.接受氨柔比星和伊立替康治疗的肺转移性大细胞神经内分泌癌长期无病生存者。
Drug Des Devel Ther. 2009 Sep 21;3:213-7. doi: 10.2147/dddt.s6423.
4
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.伊立替康、顺铂和依托泊苷用于敏感复发性小细胞肺癌的多机构II期试验。
Br J Cancer. 2004 Aug 16;91(4):659-65. doi: 10.1038/sj.bjc.6602056.
5
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.拓扑异构酶I和II抑制剂XR5000（DACA）在晚期卵巢癌患者中进行120小时静脉输注的II期研究。
Invest New Drugs. 2003 Aug;21(3):347-52. doi: 10.1023/a:1025476813365.
6
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.顺铂、伊立替康和表柔比星每3周给药一次用于晚期实体瘤患者的I期研究。
Br J Cancer. 2003 Aug 18;89(4):617-24. doi: 10.1038/sj.bjc.6601147.
7
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.顺铂、依托泊苷和伊立替康每周化疗方案用于转移性肺癌的Ⅰ/Ⅱ期试验：日本临床肿瘤学组9507研究
Br J Cancer. 2003 Mar 24;88(6):808-13. doi: 10.1038/sj.bjc.6600800.
本文引用的文献
1
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.伊立替康与依托泊苷治疗转移性非小细胞肺癌患者的II期研究。
J Clin Oncol. 1997 Jan;15(1):304-9. doi: 10.1200/JCO.1997.15.1.304.
2
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.用拓扑异构酶I抑制剂托泊替康治疗对依托泊苷和顺铂难治的小细胞肺癌患者。
J Clin Oncol. 1996 Oct;14(10):2785-90. doi: 10.1200/JCO.1996.14.10.2785.
3
Current perspectives on camptothecins in cancer treatment.喜树碱类药物在癌症治疗中的当前观点。
Br J Cancer. 1996 Aug;74(3):327-38. doi: 10.1038/bjc.1996.362.
4
DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.癌症化疗中的DNA拓扑异构酶I和II：最新进展与展望
Cancer Chemother Pharmacol. 1993;32(2):103-8. doi: 10.1007/BF00685611.
5
Phase I study of CPT-11 and etoposide in patients with refractory solid tumors.
J Clin Oncol. 1993 Oct;11(10):2030-5. doi: 10.1200/JCO.1993.11.10.2030.
6
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.伊立替康和依托泊苷联合重组人粒细胞集落刺激因子用于晚期肺癌的I期和药理学研究
J Clin Oncol. 1994 Sep;12(9):1833-41. doi: 10.1200/JCO.1994.12.9.1833.
7
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.阿霉素诱导的由哺乳动物DNA拓扑异构酶II介导的DNA损伤。
Science. 1984 Oct 26;226(4673):466-8. doi: 10.1126/science.6093249.
8
Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.嵌入型抗肿瘤药物会干扰哺乳动物DNA拓扑异构酶II的断裂-重连反应。
J Biol Chem. 1984 Jul 25;259(14):9182-7.
9
Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.喜树碱（NSC - 100880）治疗晚期胃肠道癌的II期研究
Cancer Chemother Rep. 1972 Feb;56(1):95-101.
10
Treatment of malignant melanoma with camptothecin (NSC-100880).喜树碱（NSC-100880）治疗恶性黑色素瘤
Cancer Chemother Rep. 1972 Feb;56(1):103-5.
Zotero 插件